Edition:
United Kingdom

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

16.74USD
18 May 2018
Change (% chg)

-- (--)
Prev Close
$16.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
899,693
52-wk High
$17.40
52-wk Low
$7.43

Chart for

About

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with... (more)

Overall

Beta: 1.52
Market Cap(Mil.): $3,094.92
Shares Outstanding(Mil.): 186.89
Dividend: --
Yield (%): --

Financials

  FOLD.OQ Industry Sector
P/E (TTM): -- 28.57 32.53
EPS (TTM): -0.74 -- --
ROI: -14.16 13.08 12.63
ROE: -27.45 14.80 14.50

BRIEF-Amicus Therapeutics Reports Q1 Loss Per Share Of $0.28

* AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES

08 May 2018

BRIEF-Amicus Therapeutics Prices Underwritten Offering Of Common Stock

* AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK

16 Feb 2018

BRIEF-Amicus Therapeutics Announces Public Offering Of Common Stock

* AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

14 Feb 2018

BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat

* U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

12 Feb 2018

BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study

* AMICUS THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE DATA IN POMPE DISEASE PHASE 1/2 STUDY AT 14TH ANNUAL WORLDSYMPOSIUM™

07 Feb 2018

BRIEF-Amicus Launches Galafold For Treatment Of Fabry Disease In Spain

* AMICUS THERAPEUTICS LAUNCHES GALAFOLD™ (MIGALASTAT) FOR TREATMENT OF FABRY DISEASE IN SPAIN Source text for Eikon: Further company coverage:

17 Jan 2018

BRIEF-Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln

* AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE

08 Jan 2018

BRIEF-Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat

* AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

14 Dec 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €66.81 +0.37
Shire PLC (SHP.L) 4,197.50 -1.50
Shire PLC (3159084.L) -- --
Actelion Ltd (ATLN.S) -- --

Earnings vs. Estimates